For US Trastuzumab Biosimilars, Development Time Did Not Predict Speed To Market
Executive Summary
Amgen/Allergan's Kanjinti had second longest development time among five licensed biosimilars to Genentech's Herceptin but was the first to reach market, according to a Pink Sheet timeline of development and regulatory milestones for the follow-on products.
You may also be interested in...
Dr Reddy’s De Vré On Momentum In US Biosimilars Market, Interchangeability
The global head of Dr Reddy’s biologics business unit, Raymond De Vré, discusses in an interview with Scrip how things are looking up in the US biosimilars market, why interchangeability isn’t a major concern and how galloping volume growth is being seen by the company in emerging markets.
How Risky Is Amgen's At-Risk Launch Of Herceptin, Avastin Biosimilars?
In ongoing patent litigation with Genentech, Amgen may need to reveal its counsel's advice on whether it should launch, while Genentech must produce its settlement agreements with Mylan, Celltrion, and Pfizer.
Rare Diseases: CBER Looks To ‘Lean Into’ Accelerated Approval, Align More With CDER
US FDA biologics center officials spoke about their efforts to increase collaboration and harmonization with the drugs center, and to internally involve more review disciplines in evaluating biomarker evidence, during a Reagan-Udall Foundation meeting that weighed potential use of accelerated approval for neuronopathic mucopolysaccharidoses disorders.